Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05455320 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.

Active
Registry status
Phase 3
Development phase
864
Enrollment target
20
Study locations

NCT05455320: Active Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.

NCT05455320 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 864 participants, above the 256-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (238% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05455320, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
864 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

Primary Outcome

PFS is defined as time from the date of randomization to the first documentation of disease progression, or death due to any cause, whichever is reported first.

Conditions Studied

Relapsed or Refractory Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Pomalidomide
  • DRUG Talquetamab

Study Locations (20)

Massachusetts

  • Massachusetts General - Boston
  • Boston University Medical Center - Boston
  • University of Massachusetts Medical School - Worcester

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.
  • George Washington University - Washington D.C.

Florida

  • Memorial Healthcare System - Hollywood
  • University of Miami Health System - Miami

Louisiana

  • Tulane University Hospital & Clinics - New Orleans
  • Ochsner Health System - New Orleans

Arizona

  • The University of Arizona Cancer Center - Tucson

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Connecticut

  • Norwalk Hospital-oncology - Norwalk

Illinois

  • University Of Illinois - Chicago

Trial Details

FieldValue
Enrollment Target 864 participants
Start Date 2022-10-13
Est. Completion 2029-06-30
Phase Phase 3
Janssen Research & Development

593 total trials

What the registry record for NCT05455320 still lists

NCT05455320 is an interventional study that assigns participants to a tested intervention. The registered 864 participants enrollment target is mid-sized for trials with a published cap, above the 256-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (238% higher).

The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT05455320 names 20 study sites across 15 states, led by Massachusetts, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT05455320 about?

NCT05455320 is a clinical study titled "A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment". The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (D...

What is the current status of trial NCT05455320?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2022-10-13. Estimated completion is 2029-06-30.

What conditions does trial NCT05455320 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.

What interventions are being tested in trial NCT05455320?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Talquetamab (DRUG).

Who is sponsoring clinical trial NCT05455320?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05455320 being conducted?

This trial has 20 study locations across Arizona, Arkansas, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05455320's enrollment target sits among peer trials

864 1st of 10 higher than 10 of 10 other Relapsed or Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06256588 · 864 participants · Phase 3

    A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  • NCT06527794 · 864 participants · NA

    Remote Hypertension Management for Black Patients

  • NCT05369052 · 865 participants · Phase 3

    Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

  • NCT05914116 · 862 participants · Phase 1

    A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05455320, the US trial registry maintained by the National Library of Medicine. NCT05455320 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.